CA3234080A1 - Combination comprising atogepant for treating migraine - Google Patents

Combination comprising atogepant for treating migraine Download PDF

Info

Publication number
CA3234080A1
CA3234080A1 CA3234080A CA3234080A CA3234080A1 CA 3234080 A1 CA3234080 A1 CA 3234080A1 CA 3234080 A CA3234080 A CA 3234080A CA 3234080 A CA3234080 A CA 3234080A CA 3234080 A1 CA3234080 A1 CA 3234080A1
Authority
CA
Canada
Prior art keywords
atogepant
participants
treatment
administration
alone
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3234080A
Other languages
English (en)
French (fr)
Inventor
Ramesh Boinpally
Joel TRUGMAN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Allergan Pharmaceuticals International Ltd
Original Assignee
Allergan Pharmaceuticals International Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=83899967&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA3234080(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Allergan Pharmaceuticals International Ltd filed Critical Allergan Pharmaceuticals International Ltd
Publication of CA3234080A1 publication Critical patent/CA3234080A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
CA3234080A 2021-09-27 2022-09-27 Combination comprising atogepant for treating migraine Pending CA3234080A1 (en)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US202163261731P 2021-09-27 2021-09-27
US63/261,731 2021-09-27
US202163261783P 2021-09-28 2021-09-28
US202163261782P 2021-09-28 2021-09-28
US63/261,783 2021-09-28
US63/261,782 2021-09-28
US202263336843P 2022-04-29 2022-04-29
US63/336,843 2022-04-29
US202263395134P 2022-08-04 2022-08-04
US63/395,134 2022-08-04
PCT/US2022/077061 WO2023049920A1 (en) 2021-09-27 2022-09-27 Combination comprising atogepant for treating migraine

Publications (1)

Publication Number Publication Date
CA3234080A1 true CA3234080A1 (en) 2023-03-30

Family

ID=83899967

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3234080A Pending CA3234080A1 (en) 2021-09-27 2022-09-27 Combination comprising atogepant for treating migraine

Country Status (7)

Country Link
US (6) US12350259B2 (OSRAM)
EP (1) EP4408418A1 (OSRAM)
JP (1) JP2024533756A (OSRAM)
AU (1) AU2022353124A1 (OSRAM)
CA (1) CA3234080A1 (OSRAM)
MX (1) MX2024003952A (OSRAM)
WO (1) WO2023049920A1 (OSRAM)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3102564A4 (en) 2014-02-05 2017-10-18 Merck Sharp & Dohme Corp. Tablet formulation for cgrp-active compounds
US12168004B2 (en) 2014-02-05 2024-12-17 Merck Sharp & Dohme Llc Treatment of migraine
US12383545B1 (en) 2018-06-08 2025-08-12 Allergan Pharmaceuticals International Limited Treatment of migraine
EP4188375A4 (en) 2020-07-29 2024-07-24 Allergan Pharmaceuticals International Limited MIGRAINE TREATMENT
AU2021409718A1 (en) 2020-12-22 2023-07-13 Allergan Pharmaceuticals International Limited Treatment of migraine
MX2024003952A (es) 2021-09-27 2024-05-27 Allergan Pharmaceuticals Int Ltd Combinación que comprende atogepant para tratar la migraña.

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4166452A (en) 1976-05-03 1979-09-04 Generales Constantine D J Jr Apparatus for testing human responses to stimuli
US4256108A (en) 1977-04-07 1981-03-17 Alza Corporation Microporous-semipermeable laminated osmotic system
US4265874A (en) 1980-04-25 1981-05-05 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
US5914129A (en) * 1996-07-23 1999-06-22 Mauskop; Alexander Analgesic composition for treatment of migraine headaches
US6103260A (en) 1997-07-17 2000-08-15 Mcneil-Ppc, Inc. Simethicone/anhydrous calcium phosphate compositions
WO2003080072A1 (en) 2002-03-18 2003-10-02 Cady Roger K Preemptive prophylaxis of migraine
DE10228326A1 (de) * 2002-06-25 2004-01-22 Heribert Dr.med. Bohlen Verwendung von Macrolid- und/oder Tetracyclin-Verbindungen und/oder Gyrasehemmer enthaltenden Präparationen zur Prophylaxe und therapeutischen Behandlung von Migräne und Migräne-verwandten Erkrankungen
US20040076668A1 (en) 2002-07-03 2004-04-22 Pfizer Inc. Controlled-release pharmaceutical formulations
US7205293B2 (en) 2003-03-14 2007-04-17 Merck & Co., Inc. Benodiazepine spirohydantoin CGRP receptor antagonists
AU2004222378B2 (en) 2003-03-14 2008-08-14 Merck Sharp & Dohme Corp. Carboxamide spirohydantoin CGRP receptor antagonists
JO2355B1 (en) 2003-04-15 2006-12-12 ميرك شارب اند دوم كوربوريشن Hereditary calcitonin polypeptide receptor antagonists
CA2543458A1 (en) 2003-10-24 2005-05-12 Josef Rettenmaier & Soehne Gmbh & Co., Kg Process for co-spray drying agents with dry silicified mcc
US7390798B2 (en) 2004-09-13 2008-06-24 Merck & Co., Inc. Carboxamide spirolactam CGRP receptor antagonists
ATE464305T1 (de) 2004-09-13 2010-04-15 Merck Sharp & Dohme Bicyclische anilidspirolactame als antagonisten des cgrp-rezeptors
DE102004063755A1 (de) 2004-12-29 2006-07-20 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung von CGRP-Antagonisten zur Behandlung und Vorbeugung von Hitzewallungen bei Patienten mit Prostatakrebs
CA2599925A1 (en) 2005-03-14 2006-09-21 Merck & Co., Inc. Cgrp receptor antagonists
AU2007212197B2 (en) 2006-02-09 2012-12-13 Merck Sharp & Dohme Corp. Polymer formulations of CETP inhibitors
BRPI0711352A2 (pt) 2006-05-09 2011-09-27 Merck & Co Inc composto, composição farmacêutica, e, métodos para o antagonismo de atividade receptora de cgrp em um mamìfero, e para, tratar, controlar, melhorar ou reduzir o risco de dor de cabeça, enxaqueca , ou cefaléia vascular
EP2161996B1 (en) 2007-06-05 2014-07-16 Merck Sharp & Dohme Corp. Heterocyclic carboxamide cgrp receptor antagonists
US8450327B2 (en) 2007-10-18 2013-05-28 Boehringer Ingelheim International Gmbh CGRP antagonists
WO2009065922A2 (de) 2007-11-22 2009-05-28 Boehringer Ingelheim International Gmbh Organische verbindungen
WO2009100090A1 (en) 2008-02-05 2009-08-13 Merck & Co., Inc. Prodrugs of cgrp receptor antagonist
US8044043B2 (en) 2008-04-11 2011-10-25 Bristol-Myers Squibb Company CGRP receptor antagonists
US20150023888A1 (en) 2008-09-05 2015-01-22 Map Pharmaceuticals, Inc. Method of Using Dihydroergotamine for Pre-emptive Treatment of Migraine
DK3222277T3 (da) 2009-03-31 2020-05-11 Ligand Pharm Inc Biphenylsulfonamidendothelin- og angiotensin II-receptorantagonist til behandling af glomerulosklerose og IgA-induceret nefropati
US8765763B2 (en) 2009-06-05 2014-07-01 Boehringer Ingelheim International Gmbh Substituted piperazines as CGRP antagonists
NZ605440A (en) 2010-06-10 2014-05-30 Abbvie Bahamas Ltd Solid compositions comprising an hcv inhibitor
UA113500C2 (xx) 2010-10-29 2017-02-10 Одержані екструзією розплаву тверді дисперсії, що містять індукуючий апоптоз засіб
WO2012064911A1 (en) 2010-11-12 2012-05-18 Merck Sharp & Dohme Corp. Piperidinone carboxamide indane cgrp receptor antagonists
TWI522355B (zh) 2010-11-12 2016-02-21 默沙東藥廠 六氫吡啶酮甲醯胺氮雜茚滿ｃｇｒｐ受體拮抗劑
WO2012087777A1 (en) 2010-12-22 2012-06-28 Merck Sharp & Dohme Corp. Fused heterocyclic indane carboxamide cgrp receptor antagonists
US9067941B2 (en) 2010-12-22 2015-06-30 Merck Sharp & Dohme Corp. Fused heterocyclic azaindane carboxamide CGRP receptor antagonists
EP2654726A1 (en) 2011-03-08 2013-10-30 Zalicus Pharmaceuticals Ltd. Solid dispersion formulations and methods of use thereof
EP2685826B1 (en) 2011-03-18 2016-02-03 Merck Sharp & Dohme Corp. Piperidinone carboxamide spirohydantoin cgrp receptor antagonists
US9109209B2 (en) 2011-09-08 2015-08-18 Codexis, Inc. Biocatalysts and methods for the synthesis of substituted lactams
US9487523B2 (en) 2012-03-14 2016-11-08 Merck Sharp & Dohme Corp. Process for making CGRP receptor antagonists
AU2013232191B2 (en) 2012-03-14 2017-03-30 Merck Sharp & Dohme Llc Bis-quarternary cinchona alkaloid salts as asymmetric phase transfer catalysts
CN104411295B (zh) 2012-04-25 2017-10-10 伊诺威斯药物公司 敏感化组合物和使用方法
US9174989B2 (en) 2012-05-09 2015-11-03 Merck Sharp & Dohme Corp. Process for making CGRP receptor antagonists
US9227973B2 (en) 2012-05-09 2016-01-05 Merck Sharp & Dohme Corp. Pyridine CGRP receptor antagonists
EP2846799B1 (en) 2012-05-09 2017-11-15 Merck Sharp & Dohme Corp. Spirolactam cgrp receptor antagonists
WO2013169574A2 (en) 2012-05-09 2013-11-14 Merck Sharp & Dohme Corp. Aliphatic spirolactam cgrp receptor antagonists
NZ747040A (en) 2013-03-15 2020-02-28 Tonix Pharmaceuticals Inc Eutectic formulations of cyclobenzaprine hydrochloride and amitriptyline hydrochloride
RU2690006C2 (ru) 2013-09-16 2019-05-30 Мерк Шарп И Доум Корп. Композиции антагонистов рецепторов cgrp
US20160346198A1 (en) 2014-02-05 2016-12-01 Merck Sharp & Dohme Corp. Novel disintegration systems for pharmaceutical dosage forms
US12168004B2 (en) 2014-02-05 2024-12-17 Merck Sharp & Dohme Llc Treatment of migraine
EP3102564A4 (en) 2014-02-05 2017-10-18 Merck Sharp & Dohme Corp. Tablet formulation for cgrp-active compounds
US20240180883A1 (en) 2020-12-22 2024-06-06 Allergan Pharmaceuticals International Limited Treatment of migraine
EP3110427A4 (en) 2014-02-24 2018-05-30 Urigen Pharmaceuticals, Inc. Compositions of pentosan polysulfate salts for oral administration and methods of use
AU2015305696B2 (en) 2014-08-22 2019-08-29 Pharma& Schweiz Gmbh High dosage strength tablets of rucaparib
JP6673924B2 (ja) 2015-01-23 2020-03-25 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 肝機能障害および／または腎機能障害を有する対象における疼痛を治療するためのセブラノパドール
EA201890578A1 (ru) 2015-09-24 2018-12-28 Тева Фармасьютикалз Интернэшнл Гмбх Предотвращение, лечение и снижение (персистирующей) посттравматической головной боли
US20180092899A1 (en) 2016-09-30 2018-04-05 Merck Sharp & Dohme Corp. Method of treating acute migraine with cgrp-active compound
CN110621343A (zh) 2017-03-02 2019-12-27 贝丝以色列女执事医疗中心 选择对针对降钙素基因相关肽的抗体有反应的头痛患者
TWI754772B (zh) 2017-09-06 2022-02-11 美商美國禮來大藥廠 用於治療偏頭痛之拉米迪坦(lasmiditan)與cgrp拮抗劑之組合療法
US20190135927A1 (en) 2017-09-29 2019-05-09 Bhl Patent Holdings, Llc Migraine, headache, chronic pain treatment, and prophylaxis options
AU2018362018A1 (en) 2017-11-06 2020-06-25 Auckland Uniservices Limited Peptide conjugate CGRP receptor antagonists and methods of preparation and uses thereof
US12383545B1 (en) 2018-06-08 2025-08-12 Allergan Pharmaceuticals International Limited Treatment of migraine
US20190374520A1 (en) 2018-06-08 2019-12-12 Allergan Pharmaceuticals International Limited Treatment of migraine
US20190374518A1 (en) 2018-06-08 2019-12-12 Allergan Pharmaceuticals International Limited Treatment of migraine
TWI826514B (zh) 2018-09-04 2023-12-21 美商美國禮來大藥廠 用於預防偏頭痛之拉米迪坦(lasmiditan)長期夜間投藥
WO2020150703A1 (en) 2019-01-20 2020-07-23 Biohaven Pharmaceutical Holding Company Ltd. Cgrp antagonists for treating migraine breakthrough
CA3133912A1 (en) 2019-04-18 2020-10-22 Allergan Sales, Llc Cgrp antagonists for the treatment of medication overuse headache, post-traumatic headache, post-concussion syndrome and vertigo
US20210121541A1 (en) 2019-07-05 2021-04-29 Allergan Pharmaceuticals International Limited CGRP Antagonists and Clostridial Derivatives for the Treatment of Neuropsychiatric and Neurological Disorders
AU2020355233A1 (en) 2019-09-25 2022-05-19 Allergan Pharmaceuticals International Limited Combination therapy with CGRP antagonists
WO2021087210A1 (en) * 2019-10-31 2021-05-06 R.P. Scherer Technologies, Llc Suppository capsule
EP4188375A4 (en) 2020-07-29 2024-07-24 Allergan Pharmaceuticals International Limited MIGRAINE TREATMENT
AU2021409718A1 (en) 2020-12-22 2023-07-13 Allergan Pharmaceuticals International Limited Treatment of migraine
MX2024003952A (es) 2021-09-27 2024-05-27 Allergan Pharmaceuticals Int Ltd Combinación que comprende atogepant para tratar la migraña.
AU2023231645A1 (en) 2022-03-09 2024-09-12 Allergan Pharmaceuticals International Limited Preventive treatment of migraine
WO2024081718A1 (en) 2022-10-11 2024-04-18 Allergan Pharmaceuticals International Limited Cgrp receptor antagonist for the treatment of migraine

Also Published As

Publication number Publication date
MX2024003952A (es) 2024-05-27
US20230130736A1 (en) 2023-04-27
US12350259B2 (en) 2025-07-08
JP2024533756A (ja) 2024-09-12
US20250186412A1 (en) 2025-06-12
WO2023049920A1 (en) 2023-03-30
US12465598B2 (en) 2025-11-11
US20250032466A1 (en) 2025-01-30
US12622897B2 (en) 2026-05-12
US20250032467A1 (en) 2025-01-30
US20260014127A1 (en) 2026-01-15
US20250186413A1 (en) 2025-06-12
EP4408418A1 (en) 2024-08-07
AU2022353124A1 (en) 2024-04-11

Similar Documents

Publication Publication Date Title
US12622897B2 (en) Methods of treating migraine
IL275482B1 (en) Esketamine for the treatment of depression
US11717515B2 (en) Treatment of migraine
EP3338768B1 (en) Transdermal therapeutic system containing asenapine
EP2646031B9 (en) Increasing drug bioavailability in naltrexone therapy
JP7579239B2 (ja) 鎌状赤血球症を処置するためのｐｄｅ９阻害剤
EP4410295A2 (en) Use of vibegron to treat overactive bladder
CA3224257A1 (en) Methods for treating depressive states
US20210121418A1 (en) Treatment of proteinuria
US10213394B1 (en) Composition and method for treating neurological disease
AU2021388141A1 (en) Treatment of raynaud's disease
Idelevich et al. Current pharmacotherapeutic concepts for the treatment of obesity in adults
CN118695859A (zh) 用于治疗偏头痛的包含阿托吉泮的组合
EP2705840A1 (en) Use of rifapentine in the treatment and/or prevention of active tuberculosis disease
Chung et al. Pharmacokinetics of an oral versus intranasal delivered formulation of the phosphodiesterase type 5 inhibitor vardenafil in healthy men–A Phase 1, Randomized, Open-label, Single-dose, Two-period, Two-treatment, Cross-over Study
WO2019159185A1 (en) Compositions and methods for the treatment of protein energy wasting
HK40114255A (en) Use of vibegron to treat overactive bladder

Legal Events

Date Code Title Description
MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD

Year of fee payment: 2

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20240808

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20240808

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250808

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250808